Medstar Georgetown University Hospital’s Dr Stephen Liu shares impressions on the way a 57-year-old man with ALK-positive metastatic non–small cell lung cancer was managed, highlighting the rationale for using a second-generation ALK inhibitor as treatment.
Case: A 57-Year-Old Man with ALK+ NSCLC
Initial Presentation
A 57-year-old man presented with fatigue, anorexia and occasional rib pain
PMH: unremarkable
PE: mild right-sided chest tenderness on palpation